Key Findings
A research team led by Penn State has developed a rapid diagnostic device capable of detecting lower concentrations of the two types of antibodies associated with syphilis. In tests using 36 clinical specimens from the CDC and Boca Biolistics, the device produced test line intensities 19% to 46% stronger than those of comparable devices using conventional gold nanoparticles. The most significant gains were observed in samples with the lowest antibody concentrations.
Technical Details
The improvement centers on the composition of the nanoparticles used to form the visible positive result line. While standard tests use gold nanoparticles, the team implemented a multilayer structure consisting of a silver layer sandwiched between two gold layers. This design addresses two primary technical hurdles:
- Optical Signal: Silver possesses stronger optical properties than gold, but degrades quickly when exposed to oxygen; the gold outer layers stabilize the particle.
- Particle Size: Increasing particle size to improve visibility is limited by a threshold of approximately 60 nanometers, beyond which particles clump or settle rather than flow through the device.
The multilayer approach leverages localized surface plasmon resonance, where electrons across metallic boundaries combine to create a stronger optical signal. Laboratory benchmark tests revealed that six times fewer multilayer particles were required to form a visible mark compared to gold alone, and they remained visible with three times fewer sample target molecules.
Background & Context
The current CDC diagnostic pathway requires two separate tests: a “treponemal” test to detect antibodies against Treponema pallidum and a “non-treponemal test” to identify antibodies created by cellular damage. This sequence helps clinicians distinguish between past infections, active disease, and successful treatment. The new device aims to reproduce this diagnostic sequence in a faster, point-of-care format without requiring clinicians to abandon the established pathway.
Significance & Outlook
Detecting the low-titer range is clinically critical for identifying early-stage infections, late-stage syphilis, or monitoring declining antibody levels post-treatment. By increasing the visibility of the test line at low concentrations, this technology may reduce the number of patient appointments and prevent the spread of infection to partners and infants.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
